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Abstract Cancer cell metastasis is a multi-stage process
involving invasion into surrounding tissue, intravasation,
transit in the blood or lymph, extravasation, and growth at a
new site. Many of these steps require cell motility, which is
driven by cycles of actin polymerization, cell adhesion and
acto-myosin contraction. These processes have been stud-
ied in cancer cells in vitro for many years, often with
seemingly contradictory results. The challenge now is to
understand how the multitude of in vitro observations
relates to the movement of cancer cells in living tumour
tissue. In this review we will concentrate on actin protru-
sion and acto-myosin contraction. We will begin by
presenting some general principles summarizing the
widely-accepted mechanisms for the co-ordinated regula-
tion of actin polymerization and contraction. We will then
discuss more recent studies that investigate how experi-
mental manipulation of actin dynamics affects cancer cell
invasion in complex environments and in vivo.
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Actin polymerization drives cancer cell motility
The motility of eukaryotic cells is driven by the polymer-
ization of actin monomers into polarized filaments [1, 2].
These filaments, termed F-actin, are in a constant state of
flux with new monomers being added at the ‘barbed’ or
‘plus’ end, and depolymerization at the ‘pointed’ or
‘minus’ end. Actin polymerization can be stimulated in
many ways, including increasing the rate of monomer
addition to barbed ends, nucleating new filaments,
increasing the number of barbed ends, and reducing
depolymerization [3]. Our understanding of the molecules
involved in regulating these processes has increased dra-
matically and is summarized in Fig. 1. Stated simply, FH
proteins [4] and members of the Ena/VASP family [5]
increase the rate of monomer addition to barbed ends.
Arp2/3 are components of a multimeric complex that
nucleates the formation of new actin filaments, typically
from the side of existing filaments [6]. Cofilin can increase
the number of barbed ends available for polymerization by
severing existing filaments [7]. In motile cells the pre-
dominant site of actin polymerization is proximal to the
plasma membrane, which is driven forward by the addition
of actin monomers. Exactly how actin polymerisation alters
the shape of the plasma membrane is unclear; membrane
may flow to the front of the cell as result of pushing by
polymerising actin filaments or hydrostatic pressure or it
may be delivered in vesicles. Although the actin poly-
merization machinery is not attached to the plasma
membrane, many of the regulatory factors are either
membrane-anchored small G proteins of the Rho family [8]
or phospholipids [9] (Fig. 2). This helps ensure that newly
polymerized actin filaments are oriented in the direction of
cell migration with their barbed ends directed towards the
plasma membrane. The rate of polymerization at barbed
ends is also modulated by capping proteins [10], which
stearically hinder monomer addition, and by the avail-
ability of monomers that are usually maintained in
complexes with profilin or thymosin, which are permissive
for polymerization but prevent inappropriate polymeriza-
tion [11].
The activity of the polymerization machinery is very
tightly regulated. The Arp2/3 complex is regulated by its
association with the WAVE and WASP family of WH2
domain containing proteins (WAVE1, 2, & 3, WASP and
N-WASP) that can bind both the Arp2/3 complex and actin
monomers (Fig. 2) [6, 12]. This helps to bring actin
monomers very close in proximity to the Arp2/3 complex
and thereby increases the rate of Arp2/3-mediated actin
polymerization. WASP family proteins also bind profilin
through poly-proline motifs and this further aids recruit-
ment of actin monomers to the Arp2/3 complex [13]. WH2
domain proteins are themselves subject to very tight
regulation through a conformational switch [14, 15]. The
VCA domains including the WH2 domain can be masked
by intramolecular interactions (Fig. 2); this autoinhibited
conformation can be relieved through a range of protein–
ligand interactions. Interaction with the GTP-bound form
of Cdc42, PIP2 or adaptor molecules such as WIP and Nck,
have all been shown to promote the active ‘open’ confor-
mation of WASP or N-WASP [12]. Similarly, interactions
with a multimeric complex containing Abi/Nap/PIR121 or
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Fig. 1 Patterns of actin polymerization. Actin filaments are polarised
with polymerization being catalyzed at the ‘barbed’ or ‘plus’ end
(marked with ‘+’). (a) Formin homology (FH) proteins (dimerized
green semi-circles) promote actin monomer addition to the barbed
end and then move processively with the barbed end as the actin
filament is extended. Association of actin filament takes place in FH2
domains. (b) The Arp2/3 complex (pink hexagon) nucleates a new
actin filament from the side of an existing one, resulting in an actin
branch being formed at a 70 angle to the pre-existing filament. The
Arp2/3 complex remains at the branching point, between the side of
the pre-existing filament and the pointed end of the new filament. This
process may be repeated on the same filament or on newly
synthesized filaments. (c) Severing of actin filaments by active cofilin
family proteins (red star) results in increased free barbed ends
available for actin polymerization, thereby increasing the local
density of actin filaments
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IRSp53 can enhance the activity of WAVE proteins, in
both cases GTP-bound Rac1 is a key determinant of
localization of these complexes [12, 16]. The actin binding
protein cortactin also binds to Arp3 and this helps to locate
active Arp2/3 complexes to the sides of existing actin fil-
aments leading to branched arrays of F-actin [17].
Like WAVE and WASP family proteins, FH proteins
also switch between an auto-inhibited ‘closed’ conforma-
tion and an active ‘open’ conformation [6]. Interaction with
numerous GTP-binding proteins, including Cdc42, RhoA,
RhoB and Rif, and adaptor proteins such as DIP/WISH can
stabilise the open conformation thereby promoting actin
polymerization driven by the FH2 domain [18–22]. Struc-
tural studies indicate that FH2 domains function as dimers
with one FH2 domain binding a monomer in the existing
actin filament and the other FH2 domain recruiting a new
G-actin monomer for polymerisation [23].
These complex regulatory mechanisms serve to ensure
that actin is not polymerized inappropriately and that actin
polymerization can be increased in response to appropriate
stimuli. For example, extracellular cues, including growth
factors and extracellular matrix components, control the
GTP-loading of Rac1 and Cdc42, the generation and
hydrolysis of phospholipids, and the recruitment of adaptor
protein complexes to membranes. In addition many regula-
tors of actin polymerisation are phosphorylated in response
to external stimuli; in some cases this can have very profound
affects on their function (the example of cofilin is discussed
below), while in other cases phosphorylation can affect the
magnitude of response to other regulatory inputs (for
example src-mediated phosphorylation of cortactin) [24]. In
addition, although significant attention is paid to the role of
Rho and ROCK signalling in the regulation of actin–myosin
contraction (see below), this signalling pathway also affects
the activity of proteins regulating actin polymerization
including cofilin via LIM kinase [25], profilin [26] and FH
proteins [27]. These mechanisms enable cells to change
shape and move in response to suitable extracellular stimuli
during development and in pathological situations such as
inflammation and wound healing. However, many of these
regulatory pathways also become deregulated in cancer cells
(see Table 1) and can contribute to the invasive behaviour of
cancers. It should be noted that alterations in pathways that
regulate actin dynamics may also affect growth control and
cell survival. Therefore, proteins regulating actin dynamics
may have been selected for altered expression not only based
on their pro-migratory actions, but for a more general cancer-
promoting function.
The precise mechanism by which actin polymerization
is catalyzed can have marked consequences on the overall
F-actin structure produced. Typically, molecules that pro-
mote the addition of monomers to barbed ends (FH
proteins and Ena/VASP) generate linear F-actin arrays
[28]: these are called filopodia if they extend laterally from
the cell, or microvilli if they extend dorsally (example of
filopodia in Fig. 3). Whereas Arp2/3 mediated actin poly-
merization commonly results in ‘arc-like’ sheets of F-actin









































Fig. 2 WASP, WAVE and FH protein complexes. (a) N-WASP in a
closed conformation is inactive. A transition to an open conformation
may be initiated by binding Cdc42 to the CRIB (Cdc42 and Rac
interacting/binding) domain and PIP2 to the basic (B) region. Actin
monomers may bind directly to the WH2 (WASP homology 2)
domains or via binding to Profilin (Pro) which associates with the
proline-rich domain (P-Rich). Arp2/3 associates with the central (C)
and acidic (A) domains. The WASP interacting protein (WIP) binds
to the WH1 (Wasp homology 1) region where it contributes to the
regulation of WASP activity. WAVE also exists in an inactive
conformation (not shown). Activation occurs following binding of
HSPC300 and a multimeric Abi/Nap/PIR121 complex that is
responsive to active Rac. Alternatively, Rac may associate via
IRSp53 with the P-Rich region to promote activation. Adaptor
proteins such as NCK may associate with NAP125 and/or the P-Rich
region to promote activity. Actin binds to a WH2 domain while the
Arp2/3 complex associates with the C and A domains. PIP3 binding to
the B domain has also been implicated in activation. WHD = Wave
homology domain. (b) FH proteins exist in a closed conformation
with the carboxyl terminal regions folded back upon the CRIB and
FH3 (Formin homology 3) domains. Upon association with GTPases
including; RhoA, RhoB, Cdc42 or Rif, FH proteins change confor-
mation to promote actin nucleation and polymerization. Profilin binds
to the Formin homology 1 (FH1) domain to provide a source of
monomeric actin. Diaphanous interacting proteins (DIP) bind to
Formin homology 2 (FH2) domains and stabilize the open active
conformation. Filamentous actin also binds to the FH2 domain, which
modulates elongation and blocks capping proteins from binding
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called lamellipodia that extend over the substrate (example
of lamellipodia in Fig. 3) (reviewed in [29]). Numerous
additional proteins interact with polymerized actin fila-
ments and modulate the geometry and function of the actin
structures. Fascin can bundle actin filaments to promote the
formation of filopodia and may help to shape branched F-
actin networks generated by Arp2/3 nucleation into the
parallel arrays of filaments in filopodia [30, 31] (Table 1).
Other proteins cross-link actin filaments to form a mesh-
work or connect the actin network to cell-matrix adhesions
and to the plasma membrane. The myosin family of motor
proteins can ‘walk’ along actin filaments, either carrying
cargoes or, in the case of dimeric myosins, generating
contractile force by moving two actin filaments relative to
one another [32]. Tropomyosins are actin-binding proteins
that recruit myosin to actin filaments and respond to
increased calcium concentrations by changing conforma-
tion to allow acto-myosin contraction [33].
Co-operation and plasticity in actin polymerization
mechanisms
The molecular machinery that regulates the different facets
of actin polymerization functions coordinately in most cell
Table 1 Actin regulators implicated in cancer cell motility
Protein Molecular function Actin
structures
Experimental evidence
for role in cancer motility
Deregulation in human cancer
Arp2/3 Nucleate actin filaments L/I Y +lu, br, co (with Wave 2)
DRF’s Actin polymerisation on barbed ends F Y
Ena/VASP Promote actin polymerisation on barbed ends F/L Mena + in br
Cdc42 Activates LIMK and N-WASP F Y +br
Rac1 Activates LIMK and WAVE L Y +br, pr
WAVE1,2,3 Nucleate filaments L Y (WAVE2,3,IRSp53) Wave2 + hcc, lu, br, co (with
Arp3)
LIMK Inhibits cofilin Y +br, pr
Cofilin Sever actin filaments/generate barbed ends L/I Y +rcc, scc
Cortactin Cooperates with Arp2/3 L/I Y Located on 11q amplicon
N-WASP Increase Arp2/3 activity L/I Y -br
Ezrin/
Radixin/
link F-actin to PM Mv Y Ez & Moe + in many cancers
Moesin
Fascin F-actin bundling F Y +co, scc
MIM F-actin bundling? F Y -pr, bl
Gelsolin Actin severing/capping Y +scc, pa, -ov
Profilin Maintain reservoir of G-actin Y* -br, pa, hcc
Thymosin Maintain reservoir of G-actin Y +
RhoA,C Activates ROCK1, 2 and some DRF’s SF/CA Y (amoeboid) RhoA, C + in many ca.
ROCK1,2 p [ MLC, p-MYPT1, p [ CPI-17,
p [ LIMK
SF/CA Y (amoeboid) ROCK + in pr
MRCK p [ MLC, p-MYPT1, p [ LIMK CA Y +br
MLCK p [ MLC SF Y +nsclc, co, br, gl
DAPK1 p [ MLC -scc, co, le, lu
ILK p [ MLC, p-MYPT1, p [ CPI-17 FA(SF) Y +nsclc, pa, co
PAK’s p [ MLC, p [ LIMK Y PAK1 + in many ca., PAK4+
S100A4 Myosin II binding SF Y +bl, br, co, pa, mel, rcc, scc, nsclc,
ga
Tropomyosin Stabilize actin filaments SF Y TPM1––br, nb. TPM2 + pa, scc
Regulators of the actin cytoskeleton implicated in cancer
Cytoskeletal regulators for which there is evidence either that they have a functional role in cancer cell motility (Y indicates positive role Y*
indicates negative role) or are aberrantly expressed in human cancers are listed (Cancer abbreviations are: bl––bladder, br––breast, co––colon,
ga––gastric, gl––glioblastoma, le––leukaemia, lu––lung, mel––melanoma, nb––neuroblastoma, nsclc––non small cell lung cancer, pa––pan-
creatic, pr––prostate, rcc––renal cell carcinoma, scc––squamous cell carcinoma). Actin structures with which the genes are associated are listed
(abbreviations are: CA––cortical actin, F––filodopodium, FA––focal adhesion, I––invadopodium, L––lamellopodium, Mv––microvilli, SF––
stress fibre). ‘p[’ prefix is short for phosphorylate leading to activation whereas ‘p-’ indicates phosphorylation leading to inhibition
276 Clin Exp Metastasis (2009) 26:273–287
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types. For example, cofilin and Arp2/3 co-operate to drive
maximal actin polymerization in breast cancer cells. A
localized increase in cofilin activity leads to increased
numbers of barbed ends for actin polymerization while
Arp2/3 promote the nucleation of new filaments [34, 35].
Cofilin activity is localized to a region close the plasma
membrane because this is the site where PIP2 is hydrolysed
and because of its intrinsic preference for recently poly-
merised ATP-actin filaments [36], while activation of
membrane tethered small G proteins leads to increased
Arp2/3 activity at the plasma membrane [37, 38]. It should
also be noted that in other contexts (such as if ADP-actin
filaments are severed or other co-operating mechanism are
not active) cofilin-mediated filament severing can reduce
F-actin levels. Numerous separate studies have shown that
key actin regulators become deregulated during cancer
progression (Table 1), i.e. they appear to be coordinately
up-regulated in a sub-set of motile cancer cells [39]. This
coordination makes sense if one considers the multi-step
and cyclical nature of cell motility; up-regulation of any
one of the key regulatory steps in isolation would simply
result in other regulators becoming rate-limiting thereby
producing little or no overall increase in cell motility.
Conversely, disruption of any one regulatory pathway
would likely have an effect on motility; there is wealth of
literature documenting the effects of disrupting Arp2/3,
cofilin, FH proteins and Ena/VASP on cell migration [4–7].
However, if one examines the data in more detail it
becomes clear that disruption of any particular actin reg-
ulatory mechanism fails to completely abrogate motility,
most likely due to compensatory mechanisms maintaining
actin polymerization and turn-over, thereby supporting
motility, albeit at reduced rates. A particularly striking
example, if the generation of branched actin filaments by
the Arp2/3 complex is blocked, then extensive filopodia
formation is observed which sustains cell motility [40].
Conversely, if the function of Ena/VASP proteins that
normally promote filopodia formation is blocked, then cells
extend a more persistent and uniform lamellipod leading to
increased cell speed [41]. These studies reveal some
important principles: that the different mechanisms of actin
polymerization co-operate to generate the F-actin struc-
tures used for cell motility, and that there is plasticity in the
regulation of these mechanisms that enables cells to adapt
to interference with any one mechanism. Different relative
activities of various regulators of actin polymerisation most
likely explain the diverse range of morphologies that can
be observed in motile cancer cells (Fig. 3).
Acto-myosin contraction
The ability of cancer cells to move requires force genera-
tion to overcome factors that oppose movement (e.g. cell–
cell and cell–matrix adhesions, drag, etc.). F-actin assem-
bles with myosin II filaments composed of heavy and
regulatory light chains to form a protein complex that uses
energy from ATP hydrolysis to power actin–myosin con-
traction [32, 42]. The resultant generation of contractile
force drives the morphological reorganization and extra-
cellular matrix remodelling that facilitate cell movement.
Given the profound effects that actin–myosin contractility
can have, it is not surprising that there is a sophisticated
network of regulatory components that hold a tight rein
over this process.
Phosphorylation of the myosin II light chains (MLC) is a
key mechanism for regulation of actin–myosin contractility
[43]. MLC phosphorylation promotes the release of the
Fig. 3 Diversity of actin organisation in migrating cancer cells.
Three different cancer cell lines are shown moving on a 2D substrate:
MTLn3 mammary carcinoma cell is shown in the left-hand panel with
a broad zone of F-actin at the front, called a lamellipodium, and thick
actin cables in the cell body, called stress fibres. BE colon carcinoma
cell is shown in the middle panel with prominent ‘ruffled’ zone of F-
actin at the front, called a pseudopod, and an elongated morphology.
A431 squamous cell carcinoma cell is shown in the right-hand panel
with numerous F-actin rich protrusions at the front, called filopodia
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myosin heavy chain tail allowing for assembly into fila-
ments, and facilitates the association of the myosin head
with F-actin. The myosin head uses ATP to ‘walk’ towards
the barbed end. When multimeric myosin is associated with
more than one actin filament this causes the filaments to
move relative to each another, thereby generating contrac-
tile force. MLC phosphorylation has been reported to be
mediated by numerous kinases including: the Rho-regulated
ROCK1 and ROCK2 [44], the ROCK-regulated ZIPK [45],
MRCKa and MRCKb [46, 47], ILK [48], DAPK 1 [49] and
2 [50], DRAK 1 and 2 [51], PAK [52, 53] and MLCK [54]
(Table 1). The ability of these various kinases to phos-
phorylate MLC allows for multiple signalling pathways to
converge on the regulation of actin–myosin contractility.
Although it would be difficult to define every condition and
cell type in which a specific kinase phosphorylates MLC,
studies with small molecule inhibitors indicate that ROCK1
and ROCK2 are the major calcium-independent kinases
while MLCK is the major calcium-dependent kinase.
Dephosphorylation of MLC is catalyzed by the PP1M
phosphatase complex, which is comprised of a PP1Cd
catalytic subunit, a myosin light chain binding subunit
(MBS) and a smaller M20 subunit of unknown function
[55]. The MBS is a critical component of the complex as it
brings together the phosphatase catalytic subunit with its
cognate substrate and because of the role it plays in regu-
lating phosphatase activity. An interesting recent
development is the discovery that there are five proteins
that may act as the MBS (MYPT1, MYPT2, MYPT3,
MBS85 and TIMAP) [56]. The best characterized MBS is
the ubiquitously-expressed MYPT1 protein, it appears that
the more tissue-restricted MYPT2 likely functions and is
regulated similarly [56]. The other MBS proteins have not
been studied extensively and their roles in regulating MLC
phosphorylation remains to be determined. The major site
of MYPT1 phosphorylation is Threonine 696 (numbering
relates to the human form), which inhibits phosphatase
function [57], possibly by blocking the active site or by
disrupting interaction of the catalytic subunit with phos-
phorylated substrate [58]. Kinases that have been reported
to phosphorylate Thr696 include: ROCK1 and ROCK2
[57], MRCKa and MRCKb [47, 59], ILK [60, 61], ZIPK
[62] and the DMPK [63]. Phosphorylation of Threonine
853 by ROCK has also been reported to inhibit MLC
dephosphorylation by decreasing MLC binding [57, 64].
MLC phosphorylation is also regulated by the CPI-17
protein [65] (Table 1), which when phosphorylated on
Threonine 38 potently inhibits PP1M activity by masking
the active site in the catalytic PP1Cd subunit [66]. A
number of the same kinases that phosphorylate MYPT1
have also been shown to phosphorylate CPI-17, including
ROCK1 and ROCK2 [67], ZIPK [68] and ILK [69], raising
the possibility that kinases which inhibit PP1M activity do
so by targeting multiple regulatory proteins. The closely
related proteins KEPI and PHI-1 [70, 71] also appear to
inhibit PP1C activity in a phosphorylation-dependent
manner, but their possible roles in regulating MLC phos-
phorylation have not been characterized in detail. Elevated
expression of CPI-17 in several tumour cell lines has been
reported, where inhibition of PP1M led to inactivation of
the Merlin tumour suppressor protein and consequent
oncogenic transformation [72]. An additional possibility is
that elevated CPI-17 expression and/or phosphorylation
would contribute to the metastatic ability of tumour cells.
A number of kinases, including ROCK, apparently have
two modes for elevating MLC phosphorylation, by acting as
direct MLC kinases and by inhibiting PP1M activity. There
has not been a great deal of effort spent in trying to dissect
the relative contribution of these two pathways to MLC
phosphorylation induced by a given kinase. However, one
possibility is that the major pathway for some kinases is the
phosphorylation of MYPT1 and consequent inhibition of
PP1M. As a result, a net gain in MLC phosphorylation
would actually require less kinase activity directed towards
MLC than under conditions in which PP1M was not
inhibited. A manifestation of this effect is the increased
calcium sensitivity of MLC phosphorylation and the con-
sequent actin–myosin contractile response that can be
induced by ROCK [73]. In this example, it would imply that
Ca2+ and/or calcium-regulated kinases such as MLCK or
DAPK would cooperate with ROCK to promote contractile
force generation, and contribute to metastatic behaviour.
As well as a role in facilitating MLC phosphorylation,
calcium may contribute to cancer cell metastasis by bind-
ing to proteins such as S100A4 [74]. There is very strong
evidence from clinical and experimental studies which
indicates a significant role for S100A4 overexpression in
increased metastasis and poor prognosis for a wide variety
of cancers including; breast, colorectal, pancreatic and
renal (Table 1). Intriguingly, S100A4 has an extracellular
role in promoting metastasis, possibly by inducing
remodelling of the extracellular matrix and/or through
interactions with a cell surface receptor, as well as an
intracellular role. It has been proposed that S100A4 acts by
binding to the myosin II heavy chain [75] and promotes
increased directional motility by shifting the balance
towards forward protrusions and away from side protru-
sions [76]. In addition, S100A4 may also affect actin–
myosin contractility by direct binding to F-actin [77] and to
the actin-binding protein tropomyosin [78].
Tropomyosins are derived from four distinct genes (a, b,
c, d) that are transcribed and spliced into over 40 isoforms
[33, 79]. Although they play key roles in the calcium-
responsive contraction of striated muscle, their roles in non-
muscle cells are less well defined. Different isoforms appear
to have distinct biological functions, as a result the patterns
278 Clin Exp Metastasis (2009) 26:273–287
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of expression affect how tropomyosins might affect the
actin cytoskeleton. The expression of tropomyosin isoforms
is frequently altered in tumours (Table 1). Some isoforms
appear to recruit myosin to actin filaments [80], and influ-
ence the activity of the myosin head ATPase and
contractility [81]. Tropomyosin has also been reported to
increase actin filament stiffness [82] and protect F-actin
from the actions of cofilin [83] and gelsolin [84]. However,
some isoforms actually reduce active myosin levels and
promote the association of cofilin with actin filaments,
resulting in the formation of lamellipodia [80]. To add
further complexity, isoforms are sorted to different cellular
compartments, and these distributions may change during
development or in tumour cells. As a result, actin–myosin
regulation may be affected by factors in addition to tropo-
myosin expression levels. Further research is necessary to
determine how both isoform expression and subcellular
distribution patterns contribute to tumour cell metastasis.
Coordinating polymerization and contraction
For efficient cell motility the processes of actin polymeri-
zation and contraction must be coordinated, with
polymerization occurring prior to contraction and more
proximal to the plasma membrane. The spatial and tem-
poral controls are linked; the main site of actin
polymerization is next to the plasma membrane and as the
membrane moves forward the most recently polymerized
actin will be adjacent to the membrane with older F-actin
further away. Immunofluorescence microscopy of the
leading edge of most migrating cells reveals that newly
polymerised actin close to the plasma membrane is not
associated with the contractile machinery (Fig. 4) [85].
How this spatial and temporal separation is achieved is not
clear, here we will propose some mechanisms. The sim-
plest one is that the contractile machinery is not
incorporated directly into newly polymerized actin fila-
ments, but binds after being recruited. This would
obviously take some time for the components to be
assembled depending on the affinities and concentrations
of the molecules. For example, F-actin at the extreme
leading edge of motile cells is free of tropomyosin, which
only becomes associated a few microns back from the
plasma membrane [86]. Alternatively, the mechanisms that
regulate polymerization and contraction could be coordi-
nated. Small GTPases of the Rho family regulate both the
actin polymerization machinery and the contractile
Fig. 4 Distinct organisation of
F-actin and MLC organisation
in a migrating cancer cell. F-
actin and pS19-MLC staining of
MTLn3 cell are shown in red
and green, respectively. Lower
right panel shows a line-scan of
the intensity of F-actin and
pS19-MLC staining in red and
green, respectively. Note how
the F-actin at the front of the
cell is not associated with
‘active’ MLC whereas the F-
actin at the rear is. This
organisation allows the actin at
the front of the cell to extend
away from the cell body while
the of the cell is pulled towards
the middle by thick acto-myosin
cables (yellow in merged
image)
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machinery. One possibility is that the polymerization and
contraction machinery could be activated by the same
GTPase, but with different kinetics leading to polymeri-
zation preceding contraction. For example, RhoA binds to
DRF1 and directly relieves its auto-inhibited conformation
to promote actin polymerization [4], whereas the mecha-
nisms by which it promotes acto-myosin contraction and
reduces depolymerization or severing of filaments requires
ROCK-mediated phosphorylation of various intermediate
proteins (e.g. MYPT1 to increase acto-myosin contraction
[55] or LIMK to reduce cofilin activity [25]). The conse-
quence of this could be that RhoA activates polymerization
very focally and very rapidly, but that contraction is acti-
vated more diffusely and slowly. Another possibility is that
the polymerization machinery can inhibit some of the
regulators of contraction. A major activity of Rac1 in the
cell is to promote WAVE dependent actin nucleation [87]
(Fig. 2), but it also indirectly inhibits RhoA through the
production of ROS [88] which may reduce Rho and ROCK
driven contractility during phases of Rac1-driven actin
polymerization.
A common theme in these examples is that precise
localized regulation of polymerization and contraction is
critical. Excessive or global activation can be as detri-
mental to motility as lack of activity and this should be
considered when attempting to reconcile apparently con-
tradictory findings. For example, both excess and reduced
levels of LIMK-mediated phosphorylation of cofilin have
been reported to reduce cell motility [25], this could be
explained if low levels are required at sites of actin poly-
merization to allow cofilin to generate new barbed ends for
polymerization but high levels are in contractile zones to
prevent the severing of filaments required for myosin-
mediated contractility [36]. Global LIMK activation would
reduce polymerization, while global inactivation would
reduce the number of filaments available for the contractile
machinery.
Actin organisation in complex environments
Most studies analyzing the generation of filopodia and
lamellipodia have used cells cultured on rigid 2D sub-
strates; however, these conditions are clearly different from
the environment through which cells move in vivo.
Recently, significant effort has been focused on trying to
understand how F-actin is organized in cancer cells moving
in more complex environments [89]. On thicker substrates
composed of matrix proteins, many cancer cells form
ventral actin-rich structures called invadopodia that are
associated with ECM proteolytic activity [90, 91]. These
structures have many similarities with podosomes that are
found in cells of monocytic origin. The formation of
invadopodia requires the activity of the actin nucleating
Arp2/3 complex, regulated by N-WASP and cortactin, and
the actin severing action of cofilin [92]. The ability of
cancer cells to make invadopodia often correlates with their
ability to enter the vasculature [93]. However, the holes
generated typically in the ECM by invadopodia (1–
2 microns) are small compared to the size of the cell, and
cancer cells have not been observed to move through the
areas of matrix degradation produced by invadopodia. This
may merely reflect a limitation of the experimental systems
used, but until this issue is resolved the relationship
between invadopodia and cancer cell invasion through
matrix barriers will remain a topic of lively debate.
The behaviour of cancer cells cultured in a truly 3D
matrix is different from when they are cultured on 2D
substrates: F-actin structures like lamellopodia are rarely
observed without a planar substrate, and the distinction
between the ventral and dorsal surfaces is lost [94] (note the
contrasting morphologies in Fig. 5). Cancer cells can be
observed moving in 3D matrices with morphologies ranging
from very elongated to rounded [89]. The matrix compo-
sition and density can also modulate cell motility and we are
still learning how best to model tissues architectures in vitro
(also discussed in ‘Actin dynamics in living tumours’ sec-
tion). In most cases there is a zone of actin polymerization
of variable size at the front of the cell, which is often rather
loosely termed a pseudopod (Fig. 5). The exact relationship
between a pseudopod in a 3D matrix and an invadopodium
is not entirely clear, although by definition an invadopodi-
um is associated with proteolytic activity [91]. Resolution
of this relationship would require simultaneous analysis of
actin polymerization and ECM proteolysis. A recent study
did examine these processes found that proteolytic activity
is restricted to a zone several microns behind the actin-rich
pseudopod [95], this spatial separation is not entirely con-
sistent with the definition of an invadopodium. Although
lamellipodia are rarely observed in 3D matrices because
they depend on a planar substrate to extend across, many of
the molecular players that are required for lamellopodia are
also required for cell migration in 3D environments––e.g.
Arp2/3, cofilin, WAVE [92].
Invading A431 squamous cell carcinoma cells do not
have a single distinct F-actin protrusion but instead have
numerous filopodia [89] (shown in 2D in Fig. 3). It is
tempting to speculate that these structures ‘sense’ the sur-
rounding matrix and those that extend in a favourable
direction then guide cell movement [96]. However, this
will remain a hypothesis until confirmed by experimental
studies.
It is also clear that the organization of the acto-myosin
contractile machinery can be quite different in more
complex environments. Most studies have focused on the
regulation of stress fibres, which are prominent in cells
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cultured on rigid substrates (Fig. 3); however, these
structures are much less prominent when cells are in 3D
environments [94]. In many cases the contractile machin-
ery is associated with the sub-membranous cortical actin
cytoskeleton. Much less is understood about the regulation
of this F-actin network; nonetheless it is clear that RhoA
and the ROCK kinases are critical for its maintenance. In
addition, it has recently been shown that modulation of
Dia2 [20] and PDK1 [97, 98] activity can affect cortical
actin. High levels of RhoA, RhoC or ROCK activity pro-
mote contraction of the cortical actin that is associated with
membrane blebbing [99].
Observation of cancer cells moving in 3D environments
has suggested that cancer cells can move using series of
membrane blebs. Although this type of motility had been
observed in vivo in developing fish embryos during the
1970s by Trinkaus and colleagues [100], it received little
attention until recently [101]. Strong actin–myosin con-
traction in one part of a cell may also produce a
compressive force that leads to increased hydrostatic
pressure and a localized detachment of the plasma mem-
brane from the cortical cytoskeleton which results in bleb
protrusion [99]. The cortical actin–myosin network gen-
erates a basal level of tension across a cell surface [102].
However, unlike a soap bubble in which surface tension is
more or less uniform, local differences in cortical actin–
myosin contraction produce variations in tension that affect
cell shape. Surface area will increase in regions of local-
ized relaxation whereas contraction will decrease surface
area. Consistent with this, ROCK and MLC are localised at
the rear of cells moving in this manner [103]. The gener-
ation of hydrostatic pressure would require that the
contractile machinery be attached to the plasma membrane;
in fact, interference with ERM proteins which link acto-
myosin cytoskeletal structures with the plasma membrane
reduces blebbing-mediated invasion [104]. Although
increased intracellular pressure has been observed in
blebbing mitotic cells in vitro [105], direct demonstration
of the role of hydrostatic pressure in cells moving in 3D
environments is problematic, at least in part because
techniques that measure force and elasticity such as atomic
force microscopy can not easily be used in these
environments.
As discussed above, some cancer cells invade with a
rounded morphology associated with high levels of Rho–
ROCK activity driving cortical acto-myosin contraction; in
contrast other cancer cells move with an elongated mor-
phology that does not require Rho–ROCK function [104,
106]. Instead the ROCK related kinases, MRCKa and b
function redundantly with ROCK1 and 2 to regulate acto-
myosin [47]. ROCK and MLCK have been shown to play
distinct but complementary roles in the regulation of MLC
phosphorylation, actin structures and motility of cells in 2D
tissue culture conditions [107–110]. Elevated MLCK
expression has been detected in numerous tumour types
[111–114] and cancer cell lines [115–117] suggesting that
increased MLCK activity resulting from overexpression or
increased calcium transients might act to drive cancer cell
Fig. 5 Differences between 2D
and 3D. Left-hand panels show
MTLn3 cell on 2D substrate:
note broad lamellipodium,
ventral stress fibres and flat
cross-section of the cell. Right-
hand panels show MTLn3 cell
in 3D collagen gel (inset panel
shows collagen fibres in white):
note absence of stress fibres,
more complex organisation of
the F-actin at the front of the
cell (no longer a planar
lamellipodium) and rounded
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motility in vivo, possibly in co-operation with ROCK.
ZIPK has recently been shown to be phosphorylated and
activated by ROCK [118], and can phosphorylate common
substrates including MLC [45], MYPT1 [119] and CPI-17
[68]. These findings suggest that ZIPK could amplify a
Rho–ROCK signal or that elevated ZIPK activity might
substitute for Rho–ROCK activity, to promote metastasis.
However, the exact roles played by MLCK and ZIPK in
regulating acto-myosin function in 3D environments
remains to be determined.
In addition to the diverse patterns of F-actin organiza-
tion observed in motile cancer cells [120] (Fig. 3), it is now
clear that many cancer cells exhibit significant plasticity in
the mechanisms they use to move [104]. This presents a
particular challenge when designing inhibitor strategies to
block cell movement; for example inhibition of extracel-
lular proteases causes many cancer cells to move with a
rounded, blebbing morphology [104, 121]. Constriction of
the cortical acto-myosin enables these cells to squeeze
through gaps in the surrounding matrix or deform the
matrix and thereby invade without the need for protease
function [106]. To date, this plasticity has been observed in
the experimental context; however, it may also enable
cancer cells to overcome the diverse challenges of the
metastatic process in human patients. Moving through
dense connective tissue, crossing a thin endothelial layer
and surviving the shear stresses in the circulation are likely
to require different cytoskeletal organizations. Therefore, it
may be that a high degree of plasticity in actin organization
is particularly favourable during metastasis.
Actin dynamics in living tumours
The use of 3D matrices has highlighted the diversity of
motility modes utilized by cancer cells [94]. However,
there are always concerns with experimentally generated
matrices about how they compare to the matrix surround-
ing tumours in vivo. Most experimentally generated
collagen matrices use pepsin-cleaved collagen I, which
lacks the telopeptide of native collagen, and also lacks the
cross-linking and higher order organization typical of col-
lagen matrices in tissues [122]. To circumvent these
concerns, some researchers have turned to imaging the
movement of cancer cells in living tumours [123, 124].
There are a number of methods that have been employed
for intravital imaging, including: whole body fluorescence
microscopy (most often using confocal or multiphoton
microscopes––an example is shown in Fig. 6), implanta-
tion of window chambers combined with fluorescence
microscopy and whole body bioluminescence [123–126].
These approaches have revealed some surprises: firstly the
majority of cancer cells are not motile in vivo even in
metastatic tumours [123, 124]; secondly the motile cells
frequently move in an ‘amoeboid’ manner that bears sim-
ilarities to the movement of leukocytes [127] and dispersed
Dictyostelium cells [128]. Amoeboid cell motility is fast
([1micron/min) with rapid changes in cell shape and
direction (an example is shown in Fig. 6). This leads to
cells often having an amorphous appearance. The exact
relationship between amoeboid cell motility and the
rounded, blebbing associated motility described earlier is
Fig. 6 In vivo imaging of
amoeboid cell movement. GFP
expressing A375 melanoma
cells in green, Extra Cellular
Matrix in pink, yellow outline
shows rapidly moving cell (180s
between frames, image
100 9 100 microns). Note
rapidly changing morphology
and direction of movement
(indicated with dashed white
line in last panel) and
constriction of the cell body at
various points (marked with
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not entirely clear. However, there are many similarities
including the key role of the cortical F-actin network and
the rounded cell morphologies. Gene expression profiling
of motile cells collected from metastatic tumours has
revealed that these cells coordinatedly up-regulated many
of the key actin regulators described above, including
cofilin, Arp2/3 complex subunits, N-WASP, LIMK,
ROCK1, and RhoA [39]. By combining manipulation of
these actin regulators with the in vivo imaging of tumour
cells, it is now possible to study the regulation of actin
dynamics in tumour cells in situ [123]. This type of
approach revealed that inactivation of cofilin by LIMK
reduced both tumour cell motility in vivo and metastasis
[129], suggesting that actin filament severing by cofilin
does indeed have an important in vivo. It will be interest-
ing to examine the role of other regulators of actin
polymerization in similar situations.
Live tumour cell imaging will also allow the organiza-
tion of the cytoskeleton to be analysed and should help to
address questions such as; the prevalence of filopodia and
invadopodia in motile cells in vivo, and if there are
structures analogous to lamellipodia in vivo. By imaging
GFP-tagged myosin light chain, the acto-myosin contrac-
tile machinery was found to be located around the cortex of
motile cancer cells in vivo [106]. Furthermore, the orga-
nization of MLC and the motility of these cells was ROCK-
dependent [106]. It will be fascinating to extend this type
of analysis to regulators of the actin polymerization
machinery. The behaviour of cells with increased Rho–
ROCK function following stable knockdown of the Smurf1
E3 ubiquitin ligase, which targets RhoA for degradation
[130], also has been imaged in vivo. Smurf1 knockdown
led to locally increased Rho activity around the cell cortex
resulting in a more rounded morphology of motile cells
within the tumours and an increased number of cells
observed within the vasculature [131]. Taken together,
these observations support the notion that high levels of
cortical acto-myosin contraction are associated with
amoeboid or rounded cancer cell motility and the meta-
static process. This could potentially explain the elevated
expression levels of many of the molecules involved in the
regulation of acto-myosin contraction in metastatic human
cancers.
What next?
In this review we have tried to summarize current thinking
about regulation of the actin cytoskeleton in invading
cancer cells and highlight some areas of current debate. It
is clear that there is still much we do not know, but can we
speculate what we might hope to learn in next two or three
years? Recently the number of known molecules that can
promote actin polymerization has increased but many of
these have not yet been studied in the context of cancer
biology. In fact only the regulators of the Arp2/3 complex
and cofilin have been extensively studied in cancer models.
It will be fascinating to learn about the role of the various
FH proteins and other actin nucleators, such as spire and
cordon bleu, in the migration of cancer cells and to
determine if they become aberrantly regulated in tumours.
Another area of growing interest is diverse range of mor-
phologies or ‘modes of motility’ exhibited by cancer cells;
these range from amoeboid, to elongated and collective
patterns of invasion. Many human tumours show strand
like patterns of invasion with cells often retaining cell-cell
adhesions [120]. This adds considerable complexity to the
problem of cell invasion; we need to understand how the
behaviour of many cells is coordinated so that they invade
in one direction, and explore the possibility that distinct
cells in the strands have different roles [132]. Greater
knowledge of the molecular pathways that determine the
mode of motility used by cancer cells and how switching
between different actin architectures is regulated will be
very beneficial in understanding why and how cancer cells
exit primary tumours.
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